Navigation Links
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference

rmation, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the 2007 CEUT Emerging Growth Opportunities Conference, and products in development for the treatment of Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward- looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's Annual Report on Form 10-Q for the quarter ended March 31, 2007 under the heading "Risk Factors", which is on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "Investor Relations -- SEC Filings." T
'"/>




Page: 1 2 3

Related medicine technology :

1. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/23/2009)....23/PRNewswire/--TwooftheChicagoarea,sleadingBoard...rainwomen,sbreastimaging,couplingthelatesttechnolo...rasoundwiththeabilitytohavethefullrangeofdigitalim...beforesheleavestheoffice.Drs.AhmedFaragandJoanWerb...tthecurrent6-9monthwaitforanappointmentcommonlyfou...
(Date:11/23/2009)...v.23/PRNewswire-FirstCall/--NuVasive, Inc. (Nasdaq...roductsforminimallydisruptivesurgicaltreatmentsfor...dChiefExecutiveOfficer,andMichaelJ.Lambert,Executi...edtopresentatthe21stAnnualPiperJaffrayHealthCareCo...esday,December2,2009,at10:00a.m.ET.Mr.LukianovandM...
(Date:11/23/2009)....,Nov.23/PRNewswire-FirstCall/--Immucor,Inc.(Nasda...ent-reagentsystemstothebloodtransfusionindustry,to...affray21stAnnualHealthCareConferenceinNewYork,NYwi...heCompany,spresentationisscheduledforTuesday,Decem...tationwillbeavailablethroughthe"AboutUs--InvestorI...
Breaking Medicine Technology:NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 1Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 2Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 4Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 5Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 1Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 2
... Schering-Plough,Corporation (NYSE: SGP ) today ...on (FDA) recently accepted the filing for review o...fast-dissolving, sublingual tablet.,Schering-Ploug...he treatment,of schizophrenia and acute mania or m... In accepting the NDA, the FDA indicated that asen...
...mmenting on a study,of lung transplantation for ch...ulmonologist calls the study "startling" in an edi...ine that accompanies the study., Julian Allen, M....r in,Pediatric Pulmonary Medicine at The Children,... University of Utah research team, which found tha...
Other Medicine Technology:Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 2Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 3Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 4Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis 2
(Date:11/23/2009)...ty of Michigan determined that only 663,000 of the...s C virus (HCV) infection received antiviral thera...to be declining, in part because only half of the ...ng trend continues, by 2030 less than 15% of liver...viral therapy. This study, the first to analyze n...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...ok for the high cost of drug advertising that does...ed by a University of British Columbia health poli...the Archives of Internal Medicine , examined the ...ug also known by the trade name Plavix used to pre... drug was selected to study the impact of advertis...
(Date:11/23/2009)... suffering from women,s hair loss for almost ten y...he,s sharing her progress and the secret behind he...e release of her video diaries which include a dir...reatment. , (PRWeb UK) No...Zsanett Siklosi has released the video diaries tha...
(Date:11/23/2009)...n might ease the problem, researchers say , ...bottle up their anger over unfair treatment at wor...dy indicates. , Men who consistently failed to ...low worker or supervisor were more than twice as l...se as those who vented their anger, claims a repor...
Breaking Medicine News(10 mins):Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3
...opene, other nutrients no shield against prostate ...14 (HealthDay News) -- Men who,ve been adding vita...ts to cut their risk of prostate cancer may need t...odds of prostate malignancy -- findings that are i...
...T LAKE CITY, Sept. 14 Dynatronics,Corporation (Na...th quarter,and fiscal year ended June 30, 2007. Ne...943 ($.02 per share), compared to $39,101 ($.00 pe...r the year ended June 30, 2007 were $17,837,104, c...
...NDALE, Mich., Sept. 14 Nearly 300 of,Detroit,s mo...f art to be,auctioned at the twelfth annual "ART W...5:00 p.m. on Sunday, September 23, 2007 at The Rit...tioneer Jim Miller, hors d,oeuvres, a cash bar, va...
...ANN ARBOR, Mich.---Using atom-level imaging techni...aled important structural details of an enzyme sys...ole in helping the body efficiently break down man...es. , The system involves two proteins that work ...
...Many sets of guidelines and regulations, and great...l researchers encounter if they want to use previo...arch. For one thing, this makes it extremely comp... (CBE), together with leading biobank researchers,...
...g-Term Outlook More Favorable as Drugs from Eli Li... 2016, According to a New Report ...pt. 12 Decision Resources, one of the,world,s lea...Astellas,s Flomax/Harnal, combined with the limite...
Other Medicine News:Health News:Tomato Diet Can't Guarantee Prostate Health: Study 2Health News:Tomato Diet Can't Guarantee Prostate Health: Study 3Health News:Tomato Diet Can't Guarantee Prostate Health: Study 4Health News:Dynatronics Announces Strong Fourth Quarter Profit 2Health News:Dynatronics Announces Strong Fourth Quarter Profit 3Health News:Revealing the workings of 'Mother Nature's blowtorch' 2Health News:Long-awaited international ethical guidelines for biobank researchers 2Health News:Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs 2
Auroblue
Surgicel NU-KNIT Absorbable Hemostat (oxidized regenerated cellulose)
Surgicel Fibrillar Absorbable Hemostat (oxidized regenerated cellulose)
KOWA Refkeratometer KW-2000
Medicine Products: